Blueprint Medicines

Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases, blood disorders, and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Blueprint Medicines exceeds revenue expectations, eyes growth opportunities in 2023

Blueprint Medicines delivered strong financial results and outlined growth strategies for 2023, driven by AYVAKIT's performance.
The company faces uncertainties around label negotiation but benefits from strong market access and proactive market expansion efforts.
Opportunities lie in upcoming data presentations, CDK2 program updates, and capturing additional market share in the ISM segment.

Blueprint Medicines reports strong Q1 performance and growth opportunities

Blueprint Medicines showcased strong financial performance, a robust growth strategy, and promising pipeline advancements during the Q1 earnings call. While facing challenges in managing expenses and differentiating sales, the company is well-positioned to capitalize on opportunities in driving AYVAKYT sales and educating providers on SM treatment urgency.

Blueprint Medicines reports strong Q2 results and eyes market expansion

Blueprint Medicines demonstrated solid financial performance and positive market reception for AYVAKIT and BLU-222.
While facing challenges in operational execution and market competition, the company has opportunities for growth through portfolio expansion and market diversification.
Overall, Blueprint Medicines is well-positioned to capitalize on the success of AYVAKIT and the potential of BLU-222 in driving future growth and innovation.

Blueprint Medicines excels in Q3, eyes sustainable growth in 2024

Blueprint Medicines delivered strong Q3 results with a focus on sustainable revenue growth and pipeline advancement.
The company's strengths lie in AYVAKIT's market adoption, high patient retention rates, and promising pipeline assets.
Challenges include managing operating expenses, decreasing cash burn, and expanding market penetration for AYVAKIT.
Opportunities exist in developing new assets, presenting upcoming data, and achieving significant growth in 2024.

Blueprint Medicines reports robust 2023 performance and targets $2B peak sales

Blueprint Medicines' strong 2023 performance with AYVAKIT driving revenue growth sets the stage for continued success in 2024, aiming for peak sales exceeding $2 billion.
Strategic focus on expanding market presence, advancing pipeline assets, and maintaining financial discipline positions the company for sustained growth and profitability.
Opportunities lie in maximizing AYVAKIT's market potential, leveraging BLU-808 in inflammatory disorders, and exploring strategic growth avenues in cancer treatment.

Blueprint Medicines reports robust Q1 earnings, eyes strategic partnerships

Blueprint Medicines' strong financial performance, focus on sustainable growth, and strategic expansion into new therapeutic areas position the company for long-term success. Addressing challenges in physician adoption and patient prescription rates while leveraging growth opportunities in strategic partnerships and compound expansion will be crucial for future growth.

Blueprint Medicines excels in Q3 with robust AYVAKIT sales

Blueprint Medicines delivered strong revenue growth driven by AYVAKIT sales, showcasing high compliance and demand. With a focus on long-term growth and financial stability, the company aims to expand its impact with BLU-808 and maintain strong capital allocation priorities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Blueprint Medicines Corp. is a precision therapy company, which engages in the invention of medicines for people with cancer and blood disorders. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

BioMarin Pharmaceutical

Immunovant Inc

Kymera Therapeutics

Ligand Pharmaceuticals

New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position BMRN, BPMC, IMVT, KYMR and LGND well amid volatility.

5 Biotech Stocks Worth Adding to Your Portfolio in 2024

Blueprint (BPMC) gains from better-than-expected first-quarter 2024 results, driven by robust Ayvakit sales growth. The company raises its revenue guidance for 2024.

Blueprint (BPMC) Q1 Earnings and Revenues Beat, Stock Rises

Blueprint Medicines Corporation (NASDAQ:BPMC ) Q1 2024 Earnings Conference Call May 2, 2024 8:00 AM ET Company Participants Jenna Cohen - Vice President-Investor Relations Kate Haviland - Chief Executive Officer Philina Lee - Chief Commercial Officer Fouad Namouni - President-Research & Development Mike Landsittel - Chief Financial Officer Christy Rossi - Chief Operating Officer Becker Hewes - Chief Medical Officer Conference Call Participants Brad Canino - Stifel Marc Frahm - TD Cowen Laura Prendergast - Raymond James Reni Benjamin - Citizens JMP Derek Archila - Wells Fargo Peter Lawson - Barclays Matt Biegler - Oppenheimer Ami Fadia - Needham Colleen Kusy - Baird Operator Good morning. My name is Faye, and I'll be your conference operator today.

Blueprint Medicines Corporation (BPMC) Q1 2024 Earnings Call Transcript

Blueprint Medicines (BPMC) came out with a quarterly loss of $1.32 per share versus the Zacks Consensus Estimate of a loss of $1.64. This compares to loss of $2.15 per share a year ago.

Blueprint Medicines (BPMC) Reports Q1 Loss, Tops Revenue Estimates

-- Achieved $92.5 million in AYVAKIT net product revenues in the first quarter 2024 -- -- Raising guidance to $390 million to $410 million in full year AYVAKIT net product revenues -- -- Strengthening presence in allergy and inflammation with the IND for wild-type KIT inhibitor BLU-808 on track for filing in Q2 -- CAMBRIDGE, Mass. , May 2, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today reported financial results, provided a business update for the first quarter ended March 31, 2024, and provided updated financial guidance.

Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance

Blueprint Medicines (BPMC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

CAMBRIDGE, Mass. , April 18, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m.

Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024

CAMBRIDGE, Mass., April 11, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced it will launch a webcast series to provide scientific perspectives and showcase the company's research and development strategy. The first event in this series will feature Dr. Mariana Castells, a renowned leader in mast cell research and clinical expert in allergic/inflammatory diseases, as a guest speaker.

Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics

-- AYVAKIT data in patients with indolent systemic mastocytosis show durable efficacy and favorable safety supporting long-term treatment, consistent with real-world experience observed in commercial setting -- -- Preclinical data for BLU-808, a highly selective and potent oral wild-type KIT inhibitor with best-in-class potential, supports development in chronic urticaria and other mast cell diseases; on track to submit IND to FDA in Q2 2024 -- -- Breadth of data across 9 presentations, including 2 oral, highlight scientific and clinical leadership -- CAMBRIDGE, Mass. , Feb. 23, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced PIONEER trial results highlighting the long-term efficacy and safety of AYVAKIT® (avapritinib) in patients with indolent systemic mastocytosis (ISM), as well as foundational preclinical data for BLU-808, an investigational highly selective and potent oral inhibitor of wild-type KIT.

Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting

Blueprint Medicines' Ayvakit shows strong performance in the ISM market, with revenue projections increased to $2 billion. Q4 '23 earnings highlight significant growth, with Ayvakit driving revenues up and a strong cash position despite a high burn rate. Market sentiment is robust, supported by strong analyst projections, institutional interest, and stock momentum.

Blueprint Medicines: Ayvakit Revenue Surge Fuels Optimism (Rating Upgrade)

While the top- and bottom-line numbers for Blueprint Medicines (BPMC) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Here's What Key Metrics Tell Us About Blueprint Medicines (BPMC) Q4 Earnings

Blueprint (BPMC) climbs 14% on better-than-expected fourth-quarter 2023 results, driven by increased Ayvakit sales following the drug's label expansion for the ISM indication.

Blueprint (BPMC) Q4 Earnings Beat, Stock Up as Ayvakit Shines

Blueprint Medicines Corporation (BPMC) Q4 2023 Earnings Call Transcript

Blueprint Medicines (BPMC) came out with a quarterly loss of $1.82 per share versus the Zacks Consensus Estimate of a loss of $2.04. This compares to loss of $2.65 per share a year ago.

Blueprint Medicines (BPMC) Reports Q4 Loss, Tops Revenue Estimates

Revenue from Blueprint's rare-disease drug topped fourth-quarter expectations, but BPMC stock could topple on its light outlook for the year.

Blueprint Medicines Outranks 92% Of All Stocks. But This Could Be Its Undoing.

-- Achieved $204.2 million in AYVAKIT®/AYVAKYT® (avapritinib) net product revenues in 2023, including $71.0 million in the fourth quarter -- -- Anticipate global AYVAKIT net product revenue of approximately $360 million to $390 million in 2024, representing >80 percent year-over-year growth at the midpoint -- -- Nine presentations highlighting AYVAKIT long-term safety and efficacy, BLU-808 preclinical profile, and additional data fortifying leadership in mast cell diseases accepted for presentation at 2024 AAAAI Annual Meeting -- CAMBRIDGE, Mass. , Feb. 15, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2023 and provided financial guidance.

Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Results

Besides Wall Street's top -and-bottom-line estimates for Blueprint Medicines (BPMC), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.

Seeking Clues to Blueprint Medicines (BPMC) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics

Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

CAMBRIDGE, Mass. , Feb. 1, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m.

Blueprint Medicines to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024

Here, we discuss some reasons why investing in Blueprint (BPMC) stock now may turn out to be a more prudent move than ever.

Reasons to Add Blueprint (BPMC) Stock to Your Portfolio Now

Blueprint Medicines (BPMC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Blueprint Medicines (BPMC) a New Buy Stock

BOSTON--(BUSINESS WIRE)--VantAI, a leader in the fields of drug discovery and generative AI, announced today it has entered into an amended and restated collaboration and license agreement with Blueprint Medicines, a leading precision medicine company, to design and advance novel targeted protein degrader therapies to address important areas of medical need. The agreement expands the collaboration initiated in February 2022 to include an additional target program and names VantAI and Blueprint.

VantAI Secures Renewed Support from Blueprint Medicines to Chart New Frontiers in Induced Proximity Drug Discovery

-- AYVAKIT® (avapritinib) launch in indolent systemic mastocytosis to drive strong revenue growth in 2024, with ongoing U.S. launch and recent EU approval -- -- Expanding mast cell disease leadership with oral wild-type KIT inhibitor, BLU-808, advancing into clinical development; IND submission planned in Q2 2024 -- -- Maintaining durable cash position through focused investment and global commercial execution -- -- Kate Haviland, Chief Executive Officer, to present at J.P. Morgan conference today at 10:30 a.m.

Blueprint Medicines Highlights 2024 Corporate Strategy and Business Priorities at 42nd Annual J.P. Morgan Healthcare Conference

Amgen

AstraZeneca

Bristol-Myers

Karuna Therapeutics Inc

Pfizer

Roche Holding AG

Vertex Pharmaceuticals

SPDR S&P Biotech ETF

A more favorable interest-rate outlook, an uptick in deals, and innovations in key areas like cancer and immunology are setting up biotech for a brighter 2024, analysts say.

Biotech stocks set for a rebound in 2024, analysts say

Alnylam Pharmaceuticals

argenx

Exelixis

Genmab - ADR

Incyte

Seagen

Sarepta Therapeutics

Alexion Pharma

Celgene

Horizon Pharma

Valuations in the biotech market have fallen, making it a good time for acquisitions in the industry. Investors should focus on commercial-stage biotech companies that generate revenue, as they provide a safety net in uncertain economic conditions.

News for Blueprint Medicines Stock (BPMC)